ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
ORIGINAL RESEARCH
Content of CD4+ cells expressing CD39/CD73 ectonucleotidases in children with inflammatory bowel diseases
About authors
1 National Medical Research Center for Children's Health, Moscow, Russia
2 Sechenov First Moscow State Medical University, Moscow, Russia
Correspondence should be addressed: Tatiana V. Radygina
Lomonosovsky prospekt, 2/1, Moscow, 119296, Russia; ur.liam@anigidarvt
About paper
Funding: the study was carried out on state assignment of the Ministry of Health of Russia, number АААА-А19-119013090093-2.
Acknowledgement: the authors thank all patients for participation and acknowledge the Gastroenterology Department with Hepatology Group of the National Medical Research Center for Children's Health and its collaboration.
Compliance with ethical standards: the study was approved by the Ethics Committee of the National Medical Research Center for Children's Health, Moscow (protocol № 6 dated June 11, 2019). The informed consent was submitted by all study participants.
Received: 2022-06-22
Accepted: 2022-07-16
Published online: 2022-07-31
|
Fig. 1. Stepwise gating strategies for Treg, Tact and Тh17 expressing CD39 and CD73. A. Stepwise gating for Treg and Tact: 1 — discrimination of the 'lymphoid' region based on forward scatter (FSC) and side scatter (SSC) parameters; 2 — discrimination of CD4-positive lymphocytes; 3 — discrimination of Treg as CD4+CD127lowCD25high; 4 — discrimination of Tact as CD4+CD25+CD127high; 5 — determination of CD39+ Treg; 6 — determination of CD73+ Treg; 7 — determination of CD39+ Tact; 8 — determination of CD73+ Tact. B. Stepwise gating for Тh17: 1 — discrimination of the 'lymphoid' region based on forward scatter (FSC) and side scatter (SSC) parameters; 2 — discrimination of CD3+CD4+ double-positive set; 3 — discrimination of Th17 subset; 4 — determination of CD39+ Тh17; 5 — determination of
CD73+ Тh17
Fig. 2. Proportions of cells expressing CD39 and CD73 among CD4+ lymphocytes in patients with IBD and healthy individuals (comparison group). А. p1 — level of significance for the difference between CD39+ Treg and CD73+ Treg; p2 — level of significance for the difference between CD39+ Tact and CD73+ Tact; p3 — level of significance for the difference between CD39+ Th17 and CD73+ Th17. B. p4 — level of significance for the difference between CD39+ Treg and CD73+ Treg; p5 — level of significance for the difference between CD39+ Tact and CD73+ Tact; p6 — level of significance for the difference between CD39+ Th17 and CD73+ Th17
Fig. 3. Correlations of CD39+ content in Treg vs Tact and Th17 (respectively, A and B) in pediatric patients with IBD
Fig. 4. CD39+ Treg content distributions for Crohn's disease groups 1 and 2 (respectively, A and B) and ulcerative colitis groups 3 and 4 (respectively, C and D)
Table 1. Relative counts of CD39 and CD73 ectonucleotidase-expressing cells (positivity rates) in CD4+ T lymphocyte subsets of patients with IBD and comparison group
Note: p39 — levels of significance for the differences in CD39 positivity rates between IBD and comparison group; p73 — levels of significance for the differences in CD73 positivity rates between IBD and comparison group
Table 2. Relative counts of CD39 and CD73 ectonucleotidase-expressing cells (positivity rates) in CD4+ T lymphocyte subsets of patients with Crohn's disease and ulcerative colitis at different stages and the comparison group
Note: p12 — levels of significance for the differences in CD39/CD73 positivity rates between groups 1 and 2; p34 — levels of significance for the differences in CD39/CD73 positivity rates between groups 3 and 4; p — levels of significance for the differences in CD39/CD73 positivity rates in Crohn's disease, ulcerative colitis and comparison groups; CD — Crohn's disease; UC — ulcerative colitis
